CA2548590A1 - Procedes et compositions pour recherche des predispositions a l'autisme - Google Patents
Procedes et compositions pour recherche des predispositions a l'autisme Download PDFInfo
- Publication number
- CA2548590A1 CA2548590A1 CA002548590A CA2548590A CA2548590A1 CA 2548590 A1 CA2548590 A1 CA 2548590A1 CA 002548590 A CA002548590 A CA 002548590A CA 2548590 A CA2548590 A CA 2548590A CA 2548590 A1 CA2548590 A1 CA 2548590A1
- Authority
- CA
- Canada
- Prior art keywords
- autism
- seq
- gene
- primers
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000020706 Autistic disease Diseases 0.000 title claims abstract description 112
- 206010003805 Autism Diseases 0.000 title claims abstract description 109
- 238000000034 method Methods 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title abstract description 7
- 238000012502 risk assessment Methods 0.000 title description 4
- 230000002068 genetic effect Effects 0.000 claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 206010071602 Genetic polymorphism Diseases 0.000 claims abstract description 6
- 101150083930 SLC25A12 gene Proteins 0.000 claims description 37
- 238000003752 polymerase chain reaction Methods 0.000 claims description 22
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 230000009261 transgenic effect Effects 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 101100060413 Homo sapiens SLC25A12 gene Proteins 0.000 claims description 4
- 238000012163 sequencing technique Methods 0.000 claims description 4
- 238000012408 PCR amplification Methods 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 210000004958 brain cell Anatomy 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 52
- 108700028369 Alleles Proteins 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 18
- 102000054766 genetic haplotypes Human genes 0.000 description 17
- 102100038563 Calcium-binding mitochondrial carrier protein Aralar1 Human genes 0.000 description 16
- 108091006419 SLC25A12 Proteins 0.000 description 16
- 230000005540 biological transmission Effects 0.000 description 14
- 210000000349 chromosome Anatomy 0.000 description 14
- 102000054765 polymorphisms of proteins Human genes 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 11
- 229940009098 aspartate Drugs 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 108700024394 Exon Proteins 0.000 description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 229930195712 glutamate Natural products 0.000 description 10
- 210000003470 mitochondria Anatomy 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000002407 ATP formation Effects 0.000 description 4
- 108091093088 Amplicon Proteins 0.000 description 4
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 108091006418 SLC25A13 Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 102100028523 Cytoplasmic dynein 1 intermediate chain 2 Human genes 0.000 description 3
- 102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 3
- 102100022377 Homeobox protein DLX-2 Human genes 0.000 description 3
- 101000915292 Homo sapiens Cytoplasmic dynein 1 intermediate chain 2 Proteins 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 108010024847 glutamate decarboxylase 1 Proteins 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 208000025809 Citrullinemia type II Diseases 0.000 description 2
- -1 DLXI Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101000901635 Homo sapiens Homeobox protein DLX-2 Proteins 0.000 description 2
- 101000906927 Homo sapiens N-chimaerin Proteins 0.000 description 2
- 101000595526 Homo sapiens T-box brain protein 1 Proteins 0.000 description 2
- 208000030979 Language Development disease Diseases 0.000 description 2
- 102100023648 N-chimaerin Human genes 0.000 description 2
- 101150079937 NEUROD1 gene Proteins 0.000 description 2
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 102100039902 Plasma membrane ascorbate-dependent reductase CYBRD1 Human genes 0.000 description 2
- 102100034591 Rap guanine nucleotide exchange factor 4 Human genes 0.000 description 2
- 101710204398 Rap guanine nucleotide exchange factor 4 Proteins 0.000 description 2
- 102100036083 T-box brain protein 1 Human genes 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000012093 association test Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 102200074447 rs35565687 Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- 101150064185 AGC1 gene Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000606545 Biplex Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108090000451 Calpain-10 Proteins 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 description 1
- 108010070977 Cytoplasmic Dyneins Proteins 0.000 description 1
- 102000005362 Cytoplasmic Dyneins Human genes 0.000 description 1
- 102100028530 Cytoplasmic dynein 1 intermediate chain 1 Human genes 0.000 description 1
- 102100029581 DDB1- and CUL4-associated factor 17 Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000016675 EF-hand domains Human genes 0.000 description 1
- 108050006297 EF-hand domains Proteins 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091060211 Expressed sequence tag Proteins 0.000 description 1
- 101000839032 Giardia intestinalis (strain P15) Flavohemoprotein-2 Proteins 0.000 description 1
- 102100021467 Histone acetyltransferase type B catalytic subunit Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102100030087 Homeobox protein DLX-1 Human genes 0.000 description 1
- 101710121372 Homeobox protein DLX-2 Proteins 0.000 description 1
- 102100035349 Homeobox protein DLX-6 Human genes 0.000 description 1
- 102100040229 Homeobox protein Hox-D1 Human genes 0.000 description 1
- 101000710994 Homo sapiens Calcium-binding mitochondrial carrier protein Aralar2 Proteins 0.000 description 1
- 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 1
- 101000915295 Homo sapiens Cytoplasmic dynein 1 intermediate chain 1 Proteins 0.000 description 1
- 101000917433 Homo sapiens DDB1- and CUL4-associated factor 17 Proteins 0.000 description 1
- 101000898976 Homo sapiens Histone acetyltransferase type B catalytic subunit Proteins 0.000 description 1
- 101000864690 Homo sapiens Homeobox protein DLX-1 Proteins 0.000 description 1
- 101000804582 Homo sapiens Homeobox protein DLX-6 Proteins 0.000 description 1
- 101001037162 Homo sapiens Homeobox protein Hox-D1 Proteins 0.000 description 1
- 101001109689 Homo sapiens Nuclear receptor subfamily 4 group A member 3 Proteins 0.000 description 1
- 101000745252 Homo sapiens Plasma membrane ascorbate-dependent reductase CYBRD1 Proteins 0.000 description 1
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 description 1
- 101000684826 Homo sapiens Sodium channel protein type 2 subunit alpha Proteins 0.000 description 1
- 101000684820 Homo sapiens Sodium channel protein type 3 subunit alpha Proteins 0.000 description 1
- 101001012525 Homo sapiens mRNA N(3)-methylcytidine methyltransferase METTL8 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100340130 Mus musculus Hoxd1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108700020297 NeuroD Proteins 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108700039194 Plasma membrane ascorbate-dependent reductase CYBRD1 Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 102100024694 Reelin Human genes 0.000 description 1
- 108700038365 Reelin Proteins 0.000 description 1
- 101150023455 Slc25a13 gene Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 description 1
- 102100023150 Sodium channel protein type 2 subunit alpha Human genes 0.000 description 1
- 102100023720 Sodium channel protein type 3 subunit alpha Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
- 208000031045 adult-onset type II citrullinemia Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 208000025341 autosomal recessive disease Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 108010025514 cleavase VIII Proteins 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000021005 inheritance pattern Diseases 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 102100029741 mRNA N(3)-methylcytidine methyltransferase METTL8 Human genes 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000001123 neurodevelopmental effect Effects 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 208000030683 polygenic disease Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 102220008210 rs1008642 Human genes 0.000 description 1
- 102220133958 rs1878583 Human genes 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Confectionery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52763003P | 2003-12-05 | 2003-12-05 | |
| US60/527,630 | 2003-12-05 | ||
| PCT/US2004/040444 WO2005055807A2 (fr) | 2003-12-05 | 2004-12-03 | Procedes et compositions pour recherche des predispositions a l'autisme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2548590A1 true CA2548590A1 (fr) | 2005-06-23 |
Family
ID=34676764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002548590A Abandoned CA2548590A1 (fr) | 2003-12-05 | 2004-12-03 | Procedes et compositions pour recherche des predispositions a l'autisme |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20070248956A1 (fr) |
| EP (1) | EP1697533B1 (fr) |
| AT (1) | ATE490340T1 (fr) |
| AU (1) | AU2004296804B2 (fr) |
| CA (1) | CA2548590A1 (fr) |
| DE (1) | DE602004030372D1 (fr) |
| ES (1) | ES2355242T3 (fr) |
| IL (1) | IL176121A (fr) |
| WO (1) | WO2005055807A2 (fr) |
| ZA (1) | ZA200605466B (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070292962A1 (en) * | 2006-04-10 | 2007-12-20 | Duke University | Methods and compositions for genetic markers for autism |
| WO2008091647A2 (fr) * | 2007-01-25 | 2008-07-31 | Beatrice And Samuel A. Seaver Foundation | Marqueur génétique de quotient intellectuel |
| CA2726078A1 (fr) * | 2008-06-12 | 2009-12-17 | Integragen | Combinaison d'alleles a risque associes a l'autisme |
| EP2297352A1 (fr) * | 2008-06-12 | 2011-03-23 | Integragen | Procédé de prévision de l'autisme |
| US9492797B2 (en) | 2008-09-23 | 2016-11-15 | Bio-Rad Laboratories, Inc. | System for detection of spaced droplets |
| US9132394B2 (en) | 2008-09-23 | 2015-09-15 | Bio-Rad Laboratories, Inc. | System for detection of spaced droplets |
| US9764322B2 (en) | 2008-09-23 | 2017-09-19 | Bio-Rad Laboratories, Inc. | System for generating droplets with pressure monitoring |
| US9156010B2 (en) | 2008-09-23 | 2015-10-13 | Bio-Rad Laboratories, Inc. | Droplet-based assay system |
| US8633015B2 (en) | 2008-09-23 | 2014-01-21 | Bio-Rad Laboratories, Inc. | Flow-based thermocycling system with thermoelectric cooler |
| US8709762B2 (en) | 2010-03-02 | 2014-04-29 | Bio-Rad Laboratories, Inc. | System for hot-start amplification via a multiple emulsion |
| US9417190B2 (en) | 2008-09-23 | 2016-08-16 | Bio-Rad Laboratories, Inc. | Calibrations and controls for droplet-based assays |
| US12090480B2 (en) | 2008-09-23 | 2024-09-17 | Bio-Rad Laboratories, Inc. | Partition-based method of analysis |
| US10512910B2 (en) | 2008-09-23 | 2019-12-24 | Bio-Rad Laboratories, Inc. | Droplet-based analysis method |
| US8951939B2 (en) | 2011-07-12 | 2015-02-10 | Bio-Rad Laboratories, Inc. | Digital assays with multiplexed detection of two or more targets in the same optical channel |
| WO2011120024A1 (fr) | 2010-03-25 | 2011-09-29 | Quantalife, Inc. | Génération de gouttelettes pour dosages sur gouttelettes |
| US11130128B2 (en) | 2008-09-23 | 2021-09-28 | Bio-Rad Laboratories, Inc. | Detection method for a target nucleic acid |
| CA2743542A1 (fr) * | 2008-11-12 | 2010-05-20 | University Of Utah Research Foundation | Marqueurs genetiques associes a l'autisme |
| CA2767056C (fr) | 2009-09-02 | 2018-12-04 | Bio-Rad Laboratories, Inc. | Systeme de melange de fluides par coalescence d'emulsions multiples |
| WO2011045402A1 (fr) | 2009-10-15 | 2011-04-21 | Persico Antonio M | Polymorphismes fonctionnels associés à l'autisme dans le gène slc25a12 |
| WO2011067296A1 (fr) * | 2009-12-01 | 2011-06-09 | Integragen | Combinaison de huit allèles à risque associés à l'autisme |
| US8399198B2 (en) | 2010-03-02 | 2013-03-19 | Bio-Rad Laboratories, Inc. | Assays with droplets transformed into capsules |
| CA2767113A1 (fr) | 2010-03-25 | 2011-09-29 | Bio-Rad Laboratories, Inc. | Systeme de detection pour analyses a base de gouttelettes |
| JP6155419B2 (ja) | 2010-03-25 | 2017-07-05 | バイオ−ラッド・ラボラトリーズ・インコーポレーテッド | 検出用の液滴輸送システム |
| EP2566977A1 (fr) * | 2010-05-04 | 2013-03-13 | Integragen | Nouvelle combinaison de huit allèles à risque associés à l'autisme |
| EP3574990B1 (fr) | 2010-11-01 | 2022-04-06 | Bio-Rad Laboratories, Inc. | Système de formation d'émulsions |
| CN103534360A (zh) | 2011-03-18 | 2014-01-22 | 伯乐生命医学产品有限公司 | 借助对信号的组合使用进行的多重数字分析 |
| WO2012149042A2 (fr) | 2011-04-25 | 2012-11-01 | Bio-Rad Laboratories, Inc. | Procédés et compositions pour l'analyse d'acide nucléique |
| EP2737089B1 (fr) | 2011-07-29 | 2017-09-06 | Bio-rad Laboratories, Inc. | Caractérisation de banque par essai numérique |
| WO2013155531A2 (fr) | 2012-04-13 | 2013-10-17 | Bio-Rad Laboratories, Inc. | Porte-éprouvette ayant un puits qui comporte un promoteur d'effet de mèche |
| CN109813912B (zh) * | 2019-01-04 | 2021-12-28 | 深圳大学 | 一组血清差异蛋白组合在制备用于检测孤独症的试剂中的应用 |
-
2004
- 2004-12-03 DE DE602004030372T patent/DE602004030372D1/de active Active
- 2004-12-03 CA CA002548590A patent/CA2548590A1/fr not_active Abandoned
- 2004-12-03 US US10/581,140 patent/US20070248956A1/en not_active Abandoned
- 2004-12-03 EP EP04817937A patent/EP1697533B1/fr not_active Not-in-force
- 2004-12-03 AT AT04817937T patent/ATE490340T1/de active
- 2004-12-03 AU AU2004296804A patent/AU2004296804B2/en not_active Ceased
- 2004-12-03 WO PCT/US2004/040444 patent/WO2005055807A2/fr active Application Filing
- 2004-12-03 ES ES04817937T patent/ES2355242T3/es active Active
-
2006
- 2006-06-05 IL IL176121A patent/IL176121A/en not_active IP Right Cessation
- 2006-07-03 ZA ZA200605466A patent/ZA200605466B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1697533A4 (fr) | 2008-03-05 |
| US20070248956A1 (en) | 2007-10-25 |
| IL176121A (en) | 2013-11-28 |
| IL176121A0 (en) | 2006-10-05 |
| EP1697533A2 (fr) | 2006-09-06 |
| DE602004030372D1 (de) | 2011-01-13 |
| ZA200605466B (en) | 2008-03-26 |
| WO2005055807A3 (fr) | 2006-03-09 |
| AU2004296804A1 (en) | 2005-06-23 |
| AU2004296804B2 (en) | 2011-04-14 |
| WO2005055807A2 (fr) | 2005-06-23 |
| EP1697533B1 (fr) | 2010-12-01 |
| ES2355242T3 (es) | 2011-03-24 |
| ATE490340T1 (de) | 2010-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004296804B2 (en) | Methods and compositions for autism risk assessment | |
| Ramoz et al. | Linkage and association of the mitochondrial aspartate/glutamate carrier SLC25A12 gene with autism | |
| US20150051114A1 (en) | Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets | |
| US20230193389A1 (en) | Gene and mutations thereof associated with seizure and movement disorders | |
| US20160265052A1 (en) | Gene for Identifying Individuals with Familial Dysautonomia | |
| WO2001023410A2 (fr) | Isogenes cibles a usage medicamenteux: polymorphismes dans le gene d'interleukine | |
| WO2001005832A1 (fr) | Isogenes cibles de medicament: polymorphismes dans le gene d2 du recepteur de dopamine | |
| US20050196829A1 (en) | Haplotypes of the FCER1A gene | |
| US20190276891A1 (en) | Gene for identifying individuals with familial dysautonomia | |
| WO2013142286A1 (fr) | Modifications génétiques associées à l'autisme et au phénotype autistique dans la population israélienne, et leurs procédés d'utilisation pour le diagnostic et le traitement de l'autisme | |
| US20070202502A1 (en) | Assay For Bipolar Affective Disorder | |
| WO2001094362A2 (fr) | Haplotypes du gene acp2 | |
| WO2001090117A2 (fr) | Haplotypes du gene p2ry1 | |
| WO2001014588A1 (fr) | Isogenes cibles de medicament: polymorphismes dans le gene de la chaine beta du recepteur e d'immunoglobuline | |
| WO2002022887A1 (fr) | Haplotypes du gene htr5a | |
| WO2001090126A2 (fr) | Haplotypes du gene snap29 | |
| WO2002012561A2 (fr) | Haplotypes du gene or1g1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20150407 |